Inozyme Pharma, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2018 | $67 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jan 2017 | $49 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Inozyme Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).
SEC Form D · Jun 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2020
That is all the official record says: Inozyme Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Company | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Joseph Schlessinger | Person | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Longitude Capital Partners III, LLC | Fund or asset manager | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Longitude Venture Partners III, L.P. | Venture capital | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Nea 15 GP, LLC | Other | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| NEA Partners 15, L.P. | Fund or asset manager | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| New Enterprise Associates 15, L.P. | Fund or asset manager | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pivotal bioVenture Partners Fund I, L.P. | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pivotal bioVenture Partners Fund I U.G.P., Ltd | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital LLC | Fund or asset manager | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital Management LP | Fund or asset manager | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital Master Fund LP | Fund or asset manager | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Sofinnova Management X, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Sofinnova Venture Partners X, L.P. | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Axel Bolte | Executive officer | Jun 2020 |
| Joseph Schlessinger | Executive officer | Nov 2018 |
| Axel Bolte | Director | Jun 2020 |
| Douglas Treco | Director | Jun 2020 |
| Edward Mathers | Director | Jun 2020 |
| Lynne Sullivan | Director | Jun 2020 |
| Martin Edwards | Director | Jun 2020 |
| Reinaldo Diaz | Director | Jun 2020 |
| Rob Hopfner | Director | Jun 2020 |
| Sarah Bhagat | Director | Jun 2020 |
| Joseph Schlessinger | Director | Mar 2020 |